Biotech Analysts Belanger & Gionco, along with Dr. Shoaib Ugradar, oculoplastic surgeon at Guy G. Massry, discuss various topics around thyroid eye disease (TED) and preview upcoming results from Viridian REVEAL Phase 3 trials on an Analyst/Industry conference call to be held on February 9 at 1 pm.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics price target raised to $44 from $42 at Evercore ISI
- Viridian Therapeutics initiated with a Buy at UBS
- Viridian Therapeutics: Advancing TED Pipeline, 2026 Catalysts, and New TSH Receptor Inhibitor Underpin Buy Rating
- Viridian Therapeutics: 2026 Clinical and Regulatory Catalysts, Strong Balance Sheet Support Buy Rating on VRDN
- Viridian Therapeutics: Building a Best-in-Class Thyroid Disease Franchise with Multiple Clinical Catalysts Supporting a Buy Rating